{
  "docId": "019de070-5095-745c-b54c-b78e5ae1b904",
  "docSlug": "0dc8a543e5d2136d106b59f85712c2a9",
  "documentTitle": "Taysha | IPO Presentation Deck | 66 slides",
  "authorId": "taysha",
  "authorName": "Taysha Gene Therapies",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 58,
  "pageCount": 66,
  "prevPage": 57,
  "nextPage": 59,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "Includes a visual representation of MAPT mutations linked to specific FTLD-tau subtypes and a process diagram of tau aggregation.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-5095-745c-b54c-b78e5ae1b904/58",
  "deckHref": "/decks/019de070-5095-745c-b54c-b78e5ae1b904",
  "deckJsonHref": "/decks/019de070-5095-745c-b54c-b78e5ae1b904.json",
  "deckAnchorHref": "/decks/019de070-5095-745c-b54c-b78e5ae1b904#slide-58",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.4,
        "x": 0.55,
        "y": 0.55
      },
      "kind": "diagram",
      "text": "Tau aggregation and cell-to-cell transmission pathway",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e905897-6681-4efc-a2d1-42b1c60267eb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.4,
        "x": 0.55,
        "y": 0.15
      },
      "kind": "image",
      "text": "MAPT mutations and FTLD-tau subtypes diagram",
      "attrs": null,
      "subkind": "infographic",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a16d6d8f-b1d2-4153-9635-11112c7294b5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.45,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "list",
      "text": "Mutations in MAPT lead to changes in the propensity of tau to form toxic aggregates. Tauopathies refer to a wide range of diverse diseases characterized by the aggregation of tau in neurons and/or glia, including: Alzheimer's disease (AD); Progressive supranuclear palsy (PSP); Frontotemporal dementia (FTD), and; Parkinsonism linked to chromosome 17 (FTDP-17). The estimated prevalence of these tauopathies, excluding AD is 40,000 patients in the US and EU",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c400a995-3bd7-4793-8615-d2b0dff8ff9a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.05,
        "y": 0.8
      },
      "kind": "other",
      "text": "AAV9 + Anti-Tau-miRNA + Intrathecal delivery",
      "attrs": null,
      "subkind": "unclassified",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "14c81835-8cfc-4486-9588-02c31cea57c3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.45,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "The microtubule associated protein tau (MAPT) plays a key role in numerous neurodegenerative disorders",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ad7a299a-6572-45fe-80e3-dd0b010aa210",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "causal-chain",
      "slug": null,
      "matchId": "efb5fdbe-d1fb-46d7-8aa7-6834eb676c6a",
      "evidence": "Diagram showing progression from MAPT mutation to aggregation to neurodegeneration",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 66,
      "from": 31,
      "beatId": "a2d2f153-e121-48a0-8c8f-2d7d544ceb56",
      "arcName": "AIDA",
      "arcSlug": "aida",
      "beatName": "Action",
      "beatSlug": "aida-action",
      "evidence": "The deck concludes with a call to action, presenting the company's plans for clinical and commercial development.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}